BION-1301 is a Monoclonal Antibody owned by Chinook Therapeutics, and is involved in 3 clinical trials, of which 2 are ongoing, and 1 is planned.
BION-1301 acts by inhibiting tumor necrosis factor ligand superfamily member 13 (APRIL). APRIL is highly expressed by the cancer cells, promoting tumor growth and immunosuppression. The drug candidate exhibits therapeutic intervention by inhibiting the interaction of APRIL with its receptors, transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA) and induces tumor cell death.
The revenue for BION-1301 is expected to reach a total of $109m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BION-1301 NPV Report.
BION-1301 is currently owned by Chinook Therapeutics.
BION-1301 is under development for the treatment of IgA nephropathy. It comprises of humanized IgG4 monoclonal antibody. The drug candidate targets APRIL-dependent survival in B-cell malignancies. The drug candidate is developed based on B-select antibody platform (B-select) technology. It is administered by intravenous and subcutaneous route. It was also under development for the treatment of B-cell chronic lymphocytic lymphoma, colorectal cancer and relapsed or refractory multiple myeloma.
Chinook Therapeutics Overview
Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using proprietary technology platforms such as live, attenuated, double-deleted listeria, sting pathway activators; and B-select monoclonal antibodies to create immunotherapies for the treatment of cancers, infectious and autoimmune diseases. Its products are under development and are intended for the treatment of variety of cancers, including metastatic colorectal, multiple myeloma cancers, as well as other solid tumors and lymphomas. The company collaborates with various pharmaceutical companies to expand its products, and technology platforms. It has an operational presence in The Netherlands. Chinook is headquartered in Berkeley, California, the US.
The company reported revenues of (US Dollars) US$51.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.8 million in FY2020. The operating loss of the company was US$99 million in FY2021, compared to an operating loss of US$83.9 million in FY2020. The net loss of the company was US$102.9 million in FY2021, compared to a net loss of US$81.6 million in FY2020. The company reported revenues of US$2.5 million for the third quarter ended September 2022, compared to a revenue of US$0.4 million the previous quarter.
Quick View – BION-1301
|Highest Development Stage|